(firstQuint)Phase III Study of 0.

1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis.

 0.

1% FK506 ophthalmic suspension were administered twice-a-day to patients with vernal keratoconjunctivitis in whom treatment with topical anti-allergic agents had been ineffective.

 The primary efficacy endpoint was the mean change from the baseline (before the treatment)in total score for objective clinical signs at the final observation.

 The safety of FK506 ophthalmic suspension was also investigated.

.

 Phase III Study of 0.

1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis@highlight

To investigate the efficacy and safety of FK506 ophthalmic suspension on eye symptoms in patients with vernal keratoconjunctivitis